Arbutus Biopharma Corporation Nov 15, 2024 at 5:00 AM UTC OriginalELI5 Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B Significantly greater mean declines in HBsAg levels (p
